http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 31 May 2026 19:30:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html <p>TiumBio Co., Ltd. (KOSDAQ: 321550) presented interim data from a Phase 2a trial of tosposertib combined with pembrolizumab for treating first-line recurrent or metastatic head and neck squamous cell carcinoma at the American Society of Clinical Oncology conference.</p> <p>The trial evaluated 12 first-line patients as of March 31, 2026, showing a 75% response rate, including one complete response and eight partial responses. The median progression-free survival was 10.9 months. Median overall survival had not been reached at the time of analysis.</p> <p>In patients with high CPS scores above 20, the response rate was 83%, while patients with CPS scores between 1-19 showed http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html Sun, 31 May 2026 19:30:17 -0400 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html <p>TiumBio Co., Ltd. (KOSDAQ: 321550) presented interim data from a Phase 2a trial of tosposertib combined with pembrolizumab for treating first-line recurrent or metastatic head and neck squamous cell carcinoma at the American Society of Clinical Oncology conference.</p> <p>The trial evaluated 12 first-line patients as of March 31, 2026, showing a 75% response rate, including one complete response and eight partial responses. The median progression-free survival was 10.9 months. Median overall survival had not been reached at the time of analysis.</p> <p>In patients with high CPS scores above 20, the response rate was 83%, while patients with CPS scores between 1-19 showed http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html Sun, 31 May 2026 19:30:17 -0400 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html <p>TiumBio Co., Ltd. (KOSDAQ: 321550) presented interim data from a Phase 2a trial of tosposertib combined with pembrolizumab for treating first-line recurrent or metastatic head and neck squamous cell carcinoma at the American Society of Clinical Oncology conference.</p> <p>The trial evaluated 12 first-line patients as of March 31, 2026, showing a 75% response rate, including one complete response and eight partial responses. The median progression-free survival was 10.9 months. Median overall survival had not been reached at the time of analysis.</p> <p>In patients with high CPS scores above 20, the response rate was 83%, while patients with CPS scores between 1-19 showed http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html Sun, 31 May 2026 19:30:17 -0400 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html <p>TiumBio Co., Ltd. (KOSDAQ: 321550) presented interim data from a Phase 2a trial of tosposertib combined with pembrolizumab for treating first-line recurrent or metastatic head and neck squamous cell carcinoma at the American Society of Clinical Oncology conference.</p> <p>The trial evaluated 12 first-line patients as of March 31, 2026, showing a 75% response rate, including one complete response and eight partial responses. The median progression-free survival was 10.9 months. Median overall survival had not been reached at the time of analysis.</p> <p>In patients with high CPS scores above 20, the response rate was 83%, while patients with CPS scores between 1-19 showed http://www.streetinsider.com/FDA/TiumBio+reports+tosposertib+trial+data+at+cancer+conference/26577512.html Sun, 31 May 2026 19:30:17 -0400 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/Press+Releases/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html <div class="xn-content"> <ul type="disc"><li><b><i>75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)</i></b></li><li><b><i>Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 31, 2026</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio Co., Ltd.</span> (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at <span http://www.streetinsider.com/PRNewswire/TiumBio+to+Present+Phase+2a+Interim+Data+Highlighting+Differentiated+Clinical+Profile+for+Tosposertib%28TU2218%29+plus+Pembrolizumab+in+First-Line+RM+HNSCC+at+ASCO+2026/26577509.html Sun, 31 May 2026 19:30:00 -0400 321550 321550 A.50216726 O.21612337 O.31311192 http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/Press+Releases/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html <div class="xn-content"> <ul type="disc"> <li> <i>70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data</i> </li> http://www.streetinsider.com/PRNewswire/Tiumbio+to+Present+First+Clinical+Data+for+Dual+TGF-%CE%B2VEGF+Inhibitor+Tosposertib+%28TU2218%29+at+SITC+2025%2C+%26quot%3BRobust+Response+Rate%26quot%3B/25582113.html Mon, 10 Nov 2025 08:00:00 -0400 321550 321550 A.50200218 O.31311192 O.47050987 http://www.streetinsider.com/Press+Releases/TiumBio+and+Daewon+Pharmaceutical+Successfully+Complete+Phase+2+Clinical+Trial+of+%27Merigolix+%28TU2670DW4902%29%27+for+Uterine+Fibroids/24753927.html <div class="xn-content"> <ul type="disc"><li><b>Primary Endpoint Met:</b> Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo</li><li><b>Broader Therapeutic Potential:</b> Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in-class candidate for novel drug approval and global licensing opportunities</li><li><b><span>Multi-Indication Development</span>:</b> Clinical trials are underway for three indications enhancing the asset value-uterine fibroids, endometriosis, and assisted reproductive technology (ART), the latter in collaboration with <span value="ACORN:2796070150" idsrc="xmltag.org" >Hansoh Pharma</span> in <location value="LC/cn" idsrc="xmltag.org" >China</location></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="Korea:321550" idsrc="xmltag.org" >TiumBio</span> (KRX: 321550.KQ), a http://www.streetinsider.com/Press+Releases/TiumBio+and+Daewon+Pharmaceutical+Successfully+Complete+Phase+2+Clinical+Trial+of+%27Merigolix+%28TU2670DW4902%29%27+for+Uterine+Fibroids/24753927.html Wed, 07 May 2025 08:00:00 -0400 321550 321550 A.27960701 O.29389215 O.31311192